title: Survival impact of pulmonary metastasectomy for patients with head and neck cancer.
abstract: BACKGROUND
  The purpose of this study was to evaluate the survival impact and prognostic factors of pulmonary metastasectomy in patients with pulmonary metastasis from head and neck cancer.
  
  
  METHODS
  A retrospective study of 69 patients was analyzed. Twenty-four patients (35%) underwent pulmonary metastasectomy, and the remaining 45 patients (65%) were treated with chemotherapy or best supportive care.
  
  
  RESULTS
  The 1-year overall survival (OS) of 69 patients was 28%. Pulmonary metastasectomy (p = .01) and histology (p < .001) had a significant impact on the prognosis. One-year OS of patients who underwent metastasectomy and those who did not was 90% and 35%, respectively. In the metastasectomy group, recurrence of primary ahead of lung metastasis (p = .006) and disease-free interval (DFI; ≤21.4 months; p = .046) were significant negative prognostic factors.
  
  
  CONCLUSIONS
  Pulmonary metastasectomy has an impact on survival in carefully selected patients, especially for those with a long DFI and with no recurrence of primary cancer ahead of lung metastasis.
authors.affiliation: Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Aichi, Japan.
authors.forename: Takuya
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Hasegawa
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Hanai
authors.forename: Taijirou
authors.initials: T
authors.lastname: Ozawa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Hirakawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Suzuki
authors.forename: Hiroki
authors.initials: H
authors.lastname: Okamoto
authors.forename: Ikuma
authors.initials: I
authors.lastname: Harata
mesh_terms: D000236:Adenoma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000628:therapy; D002945:Cisplatin / Q000627:therapeutic use; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D051677:Histiocytoma, Malignant Fibrous / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary* / Q000601:surgery*; D008297:Male; D059146:Metastasectomy; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D011013:Pneumonectomy; D011379:Prognosis; D012189:Retrospective Studies; D043823:Taxoids / Q000627:therapeutic use; D013908:Thoracotomy
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil
keywords: head and neck cancer; pulmonary metastasis; surgical treatment prognostic factors